Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fp MDPI; Drug: FS MDPI; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Drug: ABS eMDPI
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Treatment A – AZD7594; Drug: Treatment B – AZD7594; Drug: Treatment C – AZD7594
Sponsor: AstraZeneca
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Treatment A – AZD7594; Drug: Treatment B – AZD7594; Drug: Treatment C – AZD7594
Sponsor: AstraZeneca
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
| Related Articles |
A 12-week, Randomized, Parallel-Group, Proof-of-Concept Study of Tulobuterol Patch and Salmeterol Inhaler as Add-on Therapy in Adult-Onset Mild-to-Moderate Asthma.
Clin Exp Pharmacol Physiol. 2016 Oct 8;:
Authors: Inoue H, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Tajiri T, Iwata T, Nagasaki T, Mishima M
Abstract
Patch formulation of tulobuterol has been used in asthma treatment as a long-acting ?2 -agonist (LABA) through sustained skin absorption. Its treatment efficacy, especially in small airways, remains poorly understood. The study aim was to investigate LABA add-on effects of tulobuterol patch (TP) and salmeterol inhaler (SA) on pulmonary function, asthma control, and health status. Patients who had adult-onset under-controlled asthma, despite taking inhaled corticosteroids, were enrolled in a randomized, open-label, parallel-group, proof-of-concept study of 12-week add-on treatment with TP (n = 16) or SA (n = 17). Spirometry, impulse oscillometry (IOS), exhaled nitric oxide levels, and clinical questionnaires of asthma control, health status (St. George’s Respiratory Questionnaire: SGRQ), and symptoms were evaluated every 4 weeks. Add-on treatment of SA significantly improved the spirometric indices of small airway obstruction (forced expiratory flow between 25% and 75% of FVC: FEF25-75 , and maximum expiratory flow at 25% of FVC: MEF25 ) and IOS indices of whole respiratory resistance (resistance at 5 Hz) as compared to TP. In intra-group comparisons, add-on treatment of TP improved the scores of the asthma control test and the total SGRQ, as well as the symptom and impact components of the SGRQ. SA add-on treatment improved FEV1 and IOS parameters of resistance at 20 Hz and reactance at 5 Hz. Neither of the treatments improved exhaled nitric oxide levels. In conclusion, add-on treatment of TP improved asthma control and health status, whereas SA improved pulmonary function measures associated with large and small airway involvement among patients with adult-onset mild-to-moderate asthma. This article is protected by copyright. All rights reserved.
PMID: 27718262 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Budesonide; Drug: Formoterol
Sponsor: Intech Biopharm Ltd.
Completed – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Device: ELLIPTA DPI; Device: GSK MDI; Device: AZ MDI
Sponsor: GlaxoSmithKline
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Times of India |
Glenmark Pharma launches digital inhaler for asthma patients
Times of India Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, launched what the company touted as India's first Digital Dose Inhaler for asthma and pulmonary disease patients. The inhaler, branded as Digihaler, provides … Glenmark launches digital dose inhaler for asthma patients Glenmark's new 'digital dose inhaler' for asthma, COPD displays dose remaining in it Glenmark launches 'Digihaler' for asthma and COPD medication |
View full post on asthma – Google News
Moneycontrol.com |
Glenmark launches digital dose inhaler for asthma patients
Moneycontrol.com "This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable Asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy," the Mumbai-based firm said in a statement. |
View full post on asthma – Google News
Hindu Business Line |
Glenmark launches electronic inhaler for asthma patients
Hindu Business Line "In the case of asthma and COPD condition, where daily preventative medication is crucial for its treatment, implication of non-adherence leads to poor control symptoms, worsening the quality of life, high mortality rate which further increases health … Glenmark launches digital dose inhaler for asthma patients Glenmark launches digital inhaler for asthma, obstructive pulmonary disease |
View full post on asthma – Google News